Serge Kemps – CEO, Nipro Europe
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Address: Dorp 14a
3272 Testelt
Belgium
Tel: +32 1 333 8071
Web: http://www.pharm-olam.com/
Established and privately held since 1994, Pharm-Olam is a leading mid-size CRO with multi-national presense in over 40 countries.
Pharm-Olam delivers cost-effective, quick-to-market clinical services in emerging and traditional markets of research along with experience in a broad range of therapeutic areas and phases of development.
Pharm-Olam data services integrate randomization into EDC systems, eliminating IVRS costs, with added benefit of full inventory control over supplies.
Our multi-national pharmacovigilance team provides 24/7 coverage from our safety units in USA and Europe to electronically collect, assess and report (S)AEs, SUSARs, and ADRs for secure reporting to sponsors, regulatory agencies, sites and ethics committees.
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
See our Cookie Privacy Policy Here